Skip to content

Pfizer to Pay up to $525 Million for Lung-Focused Biotech

Pfizer’s headquarters in New York.

Pfizer’s headquarters in New York.

Photographer: Stephanie Keith/Bloomberg

Pfizer Inc. agreed to buy respiratory antiviral developer ReViral Ltd. for as much as $525 million, the Covid-19 vaccine maker’s latest move in the once-overlooked field of infectious disease.   

U.K.-based ReViral is developing therapies for respiratory syncytial virus, a common lung ailment, and Pfizer said Thursday in a statement that annual revenue could top $1.5 billion. The proposed transaction is subject to closing conditions, including receipt of regulatory approvals, Pfizer said.